RecruitingNCT03788369

Evaluation of Effectiveness and Safety of Hybrid Coronary Revascularization

Evaluation of Effectiveness and Safety of Hybrid Coronary Revascularization, a Non-randomized, Prospective, Open-label Registry in Real-world Practice


Sponsor

Seung-Jung Park

Enrollment

200 participants

Start Date

Apr 5, 2019

Study Type

OBSERVATIONAL

Conditions

Summary

This study evaluated the effectiveness and safety of Hybrid Coronary Revascularization in real-world practice.


Eligibility

Min Age: 20 Years

Inclusion Criteria3

  • Age 20 and more
  • Hybrid coronary revascularization due to multivessel coronary artery disease(must include left anterior descending artery)
  • Written consent

Exclusion Criteria2

  • Previous CABG(coronary artery bypass graft)
  • Life expectancy ≤1 year

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREHybrid Coronary Revascularization

Hybrid coronary revascularization (HCR) combines minimally invasive surgical coronary artery bypass grafting of the left anterior descending artery with percutaneous coronary intervention (PCI) of non-left anterior descending vessels.


Locations(1)

Asan Medical Center

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03788369


Related Trials